About The Chicago Metsquerade

The Chicago Metsquerade is a fundraiser for METAvivor, a non profit organization that uses 100% of donations for Metastatic Breast Cancer research. This Gala originated in Arkansas in 2016. Each year since, these Galas have spread across the country. In 2019 eight cities will host a Metsquerade including Chicago.

2019 Keynote Speaker:
Nancy Lin, MD

Nancy Lin, MD

Nancy Lin, MD is the Associate Chief of Breast Medical Oncology for the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, Director of the Metastatic Breast Cancer Program, and an Associate Professor of Medicine at Harvard Medical School.  Her research is focused upon developing novel therapies for patients with metastatic breast cancer and in understanding mechanisms of therapeutic resistance.
Dr. Lin received her undergraduate degree from Stanford University and medical degree from Harvard Medical School. She subsequently completed her residency in Internal Medicine at Brigham and Women’s Hospital and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute.
She has led multiple trials of novel systemic approaches for metastatic breast cancer, including patients with breast cancer brain metastases. She has had national and international leadership roles, including serving as the overall Principal investigator (PI) of several multi-center studies, co-chair of the Response Assessment in Neuro-Oncology metastatic working group, Chair of the Friends of Cancer-American Society Modernizing Eligibility Criteria Project-Brain Metastasis Working Group, and membership in national and international guidelines committees for the management of metastatic breast cancer.
Dr. Lin is also experienced in tissue- and blood-based translational research, and with the construction and analysis of clinical databases.  She is the PI of the breast oncology-specific tissue banking protocol at Dana-Farber, Co-Chair of the Dana-Farber/Harvard Clinical Data and Tissue Users’ Committee, and PI of active protocols allowing prospective consent for research biopsies with linked clinical data across all stages of breast cancer, and of the EMBRACE (Ending Metastatic Breast Cancer for Everyone) metastatic cohort study. She serves as the DF/HCC institutional PI for the Translational Breast Cancer Research Consortium. 

The Chicago Metsquerade is honored to have Dr Lin as our Keynote Speaker.

Why We Need You

Despite receiving appropriate treatment, thirty percent of those diagnosed with early stage breast cancer will eventually develop Stage 4-Metastatic Breast Cancer(MBC) and die. Once diagnosed with MBC, most have a median life expectancy of just 33 months. In the US alone, over 40,000 women die from this disease every year. If you know a woman who died of breast cancer, Stage 4-Metastatic Breast Cancer is what took her life. Yet of all the money dedicated to breast cancer research, less than 10% is earmarked specifically for metastatic research. METAvivor’s goal is to see MBC transition from a terminal diagnosis to that of a chronic disease with a normal life expectancy. This will only happen if we increase funding for metastatic research.